The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Lymphoseek Approved to Help Detect Lymph Nodes in Breast Cancer and Melanoma
The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.
Potential Treatment Combinations for Melanoma Identified Through Novel Screening Approach
A new drug screening method revealed that cholesterol-reducing statin drugs used in combination with cyclin-dependent kinase inhibitors might serve as an effective treatment approach for certain types of melanoma.
Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer
Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival
Nab-Paclitaxel Extends PFS Versus Standard Chemotherapy in Patients With Metastatic Melanoma
A phase III trial that compared nab-paclitaxel (nab-P; Abraxane) with dacarbazine (DTIC) in patients with metastatic malignant melanoma (MMM) found that nab-P nearly doubled the median time to progression-free survival (PFS).
Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma
Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.
Vismodegib Effective Against Skin Cancer in Patients With Basal-Cell Nevus Syndrome
The oral hedgehog pathway inhibitor vismodegib is effective for both the prevention and treatment of basal-cell carcinoma in patients with the rare disorder known as basal-cell nevus syndrome.